Global Pharma Companies Attending BioTrinity in 2010
Bringing global pharma together with R&D companies and investors is the key to BioTrinity's success. The following global pharma companies have already confirmed attendance: Novartis, Merck, Pfizer, GSK, BMS, Shire, Takeda, Boehringer, Genzyme, Teva, OSI, UCB, Daiichi Sankyo and Ranbaxy:
Sixty-five percent of the world's top 20 global pharma were respresented at senior level at BioTrinity 2009:
AstraZeneca (Alliance Manager)
Bristol Myers-Squibb (Director, External Science Technology & Licensing)
Eli Lilly (Associate Directors, Global External Development & Research)
Genzyme (US) (VP Business Development, Oncology and MS)
GSK (Director, Transactions, Worldwide Business Development)
Merck (Director, Scientific & Academic Liaison Licensing and External Research)
Novartis - Switzerland (Head of Strategic Alliances)
(OSI) Pharmaceuticals (President of Prosidion)
Pfizer (Senior Director, Worldwide Licensing and Business Development Group)
Roche (Switzerland, Global Head of Licensing)
Shire Pharma (SVP and Associate Director, Business Development)
Takeda Pharmaceuticals (Senior Director, Global Licensing & Business Development)
Teva Pharmaceutical Industries (Senior Partnering Director)